Schedule III Cannabis, Section 280E, and Federal Tax Relief

Section 280E of the Internal Revenue Code has long been one of the most severe federal tax burdens imposed on cannabis businesses. It disallows ordinary business deductions and credits for businesses trafficking in Schedule I or Schedule II controlled substances. For cannabis operators, that has often meant federal tax liability calculated without the benefit of ordinary deductions available to other businesses. 

The federal government’s 2026 medical cannabis rescheduling action changes that analysis for certain operators. In a final rule published and effective April 28, 2026, the Department of Justice and DEA placed certain FDA-approved drug products containing marijuana, and marijuana or marijuana products subject to qualifying state medical marijuana licenses, into Schedule III of the Controlled Substances Act. The same rule left marijuana outside those covered categories, including non-qualifying and adult-use marijuana activity, in Schedule I. (Federal Register) 

That distinction is now central to federal cannabis tax and business planning. 

Joseph A. Bondy, PLLC advises cannabis operators, license holders, investors, lenders, and regulated businesses on the legal and practical consequences of Schedule III treatment, DEA registration, and related regulatory and enforcement issues. 

For businesses evaluating the federal registration pathway for state medical marijuana licensees, see DEA Registration for State Medical Marijuana Licensees.

Section 280E after Schedule III rescheduling 

Section 280E applies to businesses trafficking in controlled substances listed in Schedule I or Schedule II. If a cannabis business is engaged in activity that no longer involves a Schedule I or II controlled substance, the legal basis for applying Section 280E to that qualifying activity may no longer exist. 

The April 2026 final rule states that qualifying state medical marijuana licensees will no longer be subject to the deduction disallowance imposed by Section 280E, while also making clear that the rule itself does not determine any particular taxpayer’s federal tax liability. Businesses are directed to consult tax counsel regarding their specific circumstances. 

This is not blanket tax relief for the entire cannabis industry. Instead, it is a new federal tax divide. 

The key questions are now: 

• whether the business holds a qualifying state medical marijuana license; 
• whether the relevant activity falls within the Schedule III medical cannabis framework; 
• whether any adult-use or non-qualifying activity remains subject to Schedule I treatment; 
• whether revenue, expenses, payroll, rent, inventory, and shared services can be allocated between qualifying and non-qualifying activity; 
• whether the taxpayer has sufficient records to support its position; 
• whether the business should pursue transition-year treatment, amended returns, protective refund claims, or other tax-preservation measures. 

The answer will vary by license type, state-law authorization, business activity, entity structure, tax year, and documentation. 

Treasury and IRS guidance is expected 

Treasury and IRS have announced that they plan to issue guidance addressing the federal tax consequences of DOJ’s final medical marijuana rescheduling order. Treasury has stated that rescheduling generally removes Section 280E as a bar to deductions and credits for businesses that, because of the final order, no longer traffic in Schedule I or II controlled substances under the Controlled Substances Act. (U.S. Department of the Treasury) 

Treasury has also stated that expected guidance should address businesses with multiple activities, including the application of Section 280E only to activities related to trafficking in Schedule I or II controlled substances, such as through expense apportionment. 

That forthcoming guidance will be especially important for: 

• medical cannabis licensees; 
• dual medical/adult-use operators; 
• vertically integrated cannabis businesses; 
• dispensaries with mixed medical and adult-use sales; 
• management companies serving licensed cannabis entities; 
• multi-state operators; 
• investors and lenders evaluating cannabis financial statements; 
• buyers and sellers in cannabis transactions; 
• businesses considering amended returns or protective refund claims. 

Until formal guidance is issued, cannabis operators should avoid assuming that Section 280E relief applies uniformly across an entire business, license portfolio, or tax year. 

Transition-year treatment 

Treasury has stated that expected guidance should include a transition rule providing that, for purposes of Section 280E, rescheduling generally will be considered to first apply for a business’s full taxable year that includes the effective date of the final order, for activities that do not involve Schedule I or II controlled substances as a result of the final order. 

This will be significant for qualifying medical cannabis businesses. 

For a calendar-year taxpayer, transition-year treatment may permit qualifying medical cannabis activity to be treated as outside Section 280E for the full taxable year that includes April 28, 2026, rather than only for the period after the effective date. 

But transition-year treatment should not be overstated. It does not necessarily provide full retroactive relief for closed prior tax years. It also does not necessarily apply to adult-use activity, non-qualifying products, unlicensed activity, or revenue streams that remain connected to Schedule I marijuana. 

Operators should evaluate: 

• whether they qualify for transition-year relief; 
• whether they use a calendar year or fiscal year; 
• whether medical and adult-use revenue can be separated; 
• whether shared expenses can be allocated; 
• whether records support the claimed treatment; 
• whether disclosures, reserves, protective claims, or amended returns are appropriate. 

A transition-year position may be valuable. It must also be entirely supportable. 

Retrospective relief and prior tax years 

The April 2026 final rule encourages the Secretary of the Treasury to consider providing retrospective relief from Section 280E liability for taxable years in which a state licensee operated under a state medical marijuana license. The rule also states that it does not itself determine federal tax liability, and that state licensees should consult tax counsel regarding the applicability of Section 280E to their specific circumstances. 

Even though Treasury and IRS have signaled support for guidance that may provide transition-year relief, and the final rule encourages Treasury to consider retrospective relief, operators should not assume that prior-year relief is automatic. 

Businesses may need to evaluate whether to file protective refund claims, amended returns, or other tax-preservation documents. That analysis should account for: 

• statutes of limitation; 
• prior-year medical license status; 
• whether the relevant tax years remain open; 
• whether the business had adult-use revenue; 
• whether records support medical/adult-use allocation; 
• whether prior tax positions were disclosed; 
• whether state tax treatment follows federal treatment; 
• whether pursuing a refund may increase audit risk; 
• whether investors, lenders, buyers, or sellers expect refund claims to be pursued. 

Protective refund and amended-return strategy should be coordinated among legal counsel, tax counsel, CPAs, and financial advisors. The goal is to preserve potentially valuable rights without taking unsupported tax positions. 

Medical versus adult-use allocation 

The current federal framework creates a sharp distinction between qualifying medical cannabis activity and activity that remains Schedule I. For dual-license operators, that distinction may become the central tax issue. 

A business with both medical and adult-use operations may need to allocate: 

• gross receipts; 
• cost of goods sold; 
• inventory; 
• payroll; 
• rent; 
• utilities; 
• management fees; 
• professional fees; 
• marketing expenses; 
• security expenses; 
• debt service; 
• shared services; 
• state and local tax liabilities. 

The allocation method should be legally and economically defensible. It should also be supported by contemporaneous records, not reconstructed after an IRS inquiry. 

Operators should consider whether their accounting systems separately track medical and adult-use sales, inventory, personnel, facilities, expenses, intercompany charges, and customer transactions. If they do not, the business may need to revise accounting and compliance practices immediately. 

The question is not simply whether the company has a medical cannabis license. The question is whether the company can prove which activities are qualifying Schedule III medical activities and which activities remain Schedule I. 

Multi-activity businesses and expense apportionment 

Many cannabis businesses do not operate through a single, clean line of activity. They may have multiple licenses, multiple entities, shared employees, centralized management, common branding, shared facilities, intercompany service agreements, or mixed medical and adult-use inventory. 

Treasury has indicated that forthcoming guidance is expected to address how Section 280E applies to businesses with multiple activities, including through expense apportionment. 

This may be one of the most critical issues for dual-use cannabis operators. 

Problem areas may include: 

• shared dispensary space; 
• shared payroll; 
• centralized management companies; 
• common marketing and branding; 
• intercompany service agreements; 
• related-party rent; 
• shared cultivation or processing facilities; 
• mixed medical and adult-use inventory; 
• common financing arrangements; 
• state license structures that do not align neatly with federal tax categories. 

A cannabis operator claiming Section 280E relief should be prepared to explain not only why some of its activity qualifies, but also how it identified and allocated the expenses connected to qualifying and non-qualifying activity. 

DEA registration and tax posture 

DEA registration may become an important part of the tax record for qualifying medical cannabis businesses. 

The April 2026 final rule establishes an expedited registration process for entities holding state medical marijuana licenses, enabling qualifying entities to engage in the manufacture, distribution, or dispensing of marijuana for medical purposes under federal law, subject to the requirements of the Controlled Substances Act and treaty obligations. (Federal Register) 

For tax purposes, DEA registration is not merely a regulatory formality. It may also help document the operator’s position that certain activity falls within the federally recognized medical cannabis channel rather than Schedule I activity. 

Medical cannabis operators should evaluate: 

• whether they qualify for DEA registration; 
• whether registration is required for their business model; 
• whether the registration category matches actual operations; 
• whether medical operations are separated from adult-use operations; 
• whether DEA registration records support the business’s Section 280E position; 
• whether tax, accounting, and compliance records are corroborative. 

DEA registration strategy and Section 280E strategy should be coordinated. Treating them as separate issues may create avoidable risk. 

For businesses preparing to file through the DEA medical marijuana application portal, see the DEA Medical Marijuana Application Guide.

Adult-use cannabis remains subject to Section 280E risk 

Adult-use cannabis has not received the same federal treatment as qualifying medical marijuana. The April 2026 final rule states that any form of marijuana other than an FDA-approved drug product or marijuana subject to a state medical marijuana license remains a Schedule I controlled substance. 

That means adult-use cannabis businesses should continue to assume that Section 280E applies unless and until there is further federal action. 

For dual-license operators, this creates a mixed-status problem. A business may have some activity that is potentially outside Section 280E and other activity that remains subject to it. Operators should not apply medical cannabis relief across the entire enterprise without analyzing licenses, products, revenue streams, operations, and records. 

For broader New York cannabis licensing, compliance, business-structure, and federal-state regulatory guidance, see New York Cannabis Lawyer.

Adult-use exposure may also affect: 

• investor disclosures; 
• lender diligence; 
• tax reserves; 
• transaction pricing; 
• operating agreements; 
• management agreements; 
• lease covenants; 
• enforcement risk; 
• financial projections. 

The federal tax benefit of Schedule III may be substantial, but it is not available simply because a business participates in the cannabis industry. 

Business continuity, compliance, and enforcement risk 

The tax consequences of Schedule III cannot be separated from compliance and enforcement risk. 

A cannabis business seeking Section 280E relief should be prepared to show that its claimed tax position is consistent with its licenses, records, DEA registration posture, operating practices, and federal law. A business that claims medical Schedule III tax treatment while operating in a materially adult-use or mixed-use manner may invite scrutiny and enforcement. 

Relevant questions include: 

• whether the business is operating within the scope of its state medical marijuana license; 
• whether the business has applied for or obtained DEA registration where appropriate; 
• whether medical and adult-use activity are operationally distinct; 
• whether books and records support the claimed allocation; 
• whether tax returns are consistent with regulatory filings; 
• whether contracts and investor materials accurately describe the business’s federal risk; 
• whether the business can continue operations if guidance, registration status, or litigation changes. 

Schedule III may create opportunities. It also creates requirements for an even higher caliber of proof. 

Transaction, financing, and investor implications 

Section 280E relief may materially affect cannabis business valuation. But projected tax savings should be treated carefully. 

Investors, lenders, buyers, sellers, landlords, and management companies should evaluate whether claimed Section 280E relief is supported by: 

• qualifying state medical license status; 
• DEA registration posture; 
• medical/adult-use separation; 
• books and records; 
• tax-return positions; 
• pending or anticipated Treasury and IRS guidance; 
• reserves for uncertain tax positions; 
• litigation or administrative risk; 
• contract provisions addressing changes in federal law. 

By way of examples: A buyer should not accept a post-280E projected earnings adjustment without diligence. A lender should not rely on projected tax savings without reviewing the legal basis. A seller should not overstate tax relief in offering materials. A landlord, investor, or management company should understand whether the relevant business activity remains exposed to Schedule I treatment. 

Section 280E relief may create value. It will also invariably create disputes. 

For disputes involving cannabis ownership, control, investors, management agreements, financing, license control, or enforcement exposure, see New York Cannabis Disputes Lawyer.

Practical steps for cannabis businesses 

Medical cannabis operators and dual-license businesses should consider taking the following steps now: 

1. Confirm qualifying medical status 

Determine whether the business’s licenses, products, and activities fall within the medical cannabis framework recognized by the federal rescheduling order. 

2. Evaluate DEA registration 

Assess whether the business qualifies for DEA registration and whether registration should be part of the company’s compliance and tax-support strategy. 

DEA has assured expedited review for cannabis registration applications submitted before June 26, 2026. Applicants who file by this date are allowed to operate pursuant to their state-issued licenses pending a decision on their application.    

3. Separate medical and adult-use activity 

Review whether revenue, inventory, personnel, expenses, facilities, and records can be separated by medical and adult-use activity. 

4. Coordinate legal and tax analysis 

Work in conjunction with experienced counsel and tax professionals before changing tax positions, filing amended returns, claiming deductions, or pursuing refund claims. 

5. Preserve records 

Maintain documentation supporting license status, medical sales, adult-use sales, expense allocation, DEA registration posture, and prior-year medical activity. 

6. Evaluate protective filings 

Consider whether protective refund claims, amended returns, or other preservation measures are appropriate for open tax years. 

7. Update contracts and disclosures 

Review operating agreements, investor materials, loan documents, leases, purchase agreements, management contracts, and tax-distribution provisions. 

8. Monitor Treasury and IRS guidance 

Expected guidance may affect return positions, allocation methods, transition-year treatment, and prior-year strategy. 

Legal counsel for Schedule III and Section 280E cannabis tax strategy 

Joseph A. Bondy, PLLC advises cannabis operators and stakeholders on federal regulatory issues arising from Schedule III medical cannabis rescheduling, including: 

• Schedule III medical cannabis strategy; 
• DEA registration; 
• coordination with CPAs and tax counsel; 
• contract provisions tied to rescheduling; 
• cannabis business conflicts: control, valuation, and federal law changes; 
• regulatory and enforcement risk assessment. 

Federal rescheduling may create meaningful relief for qualifying medical cannabis businesses. It also creates new legal distinctions that must be handled carefully. 

Contact Joseph A. Bondy, PLLC to evaluate your cannabis business’s Schedule III eligibility, DEA registration strategy, and medical/adult-use allocation issues. 

Disclaimer 

This page is for informational purposes only and does not constitute legal or tax advice. Reading this page or contacting Joseph A. Bondy, PLLC does not create an attorney-client relationship. Cannabis businesses should consult legal and tax professionals before taking any position concerning Section 280E, Schedule III treatment, DEA registration, amended returns, refund claims, expense allocation, transition-year treatment, or federal tax reporting.